I just bought a bottle of this stuff from amazon:
http://www.amazon.co...0?ie=UTF8&psc=1
Started adding a tbsp of potato starch to my morning soylent.
http://quackfiles.bl...cs-warning.html
Posted 29 January 2014 - 12:17 PM
I just bought a bottle of this stuff from amazon:
http://www.amazon.co...0?ie=UTF8&psc=1
Started adding a tbsp of potato starch to my morning soylent.
Posted 29 January 2014 - 02:48 PM
Just to clarify...I'm recommending PREbiotics first. Prebiotics = food for good bacteria. Probiotics = good bacteria themselves. I think that most people already have the good bacteria, they just need to feed them (obviously, there will be exceptions). In most cases, probiotics are probably unnecessary. =)I just bought a bottle of this stuff from amazon:
http://www.amazon.co...0?ie=UTF8&psc=1
Started adding a tbsp of potato starch to my morning soylent.
http://quackfiles.bl...cs-warning.html
Posted 29 January 2014 - 03:01 PM
Just to clarify...I'm recommending PREbiotics first. Prebiotics = food for good bacteria. Probiotics = good bacteria themselves. I think that most people already have the good bacteria, they just need to feed them (obviously, there will be exceptions). In most cases, probiotics are probably unnecessary. =)
I'll post abstracts to all of the 2014 studies that I'm currently going through in another post. Give me just one minute....
Posted 29 January 2014 - 03:04 PM
Cell. 2014 Jan 16;156(1-2):84-96. doi: 10.1016/j.cell.2013.12.016. Epub 2014 Jan 9.
Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits.De Vadder F1, Kovatcheva-Datchary P2, Goncalves D1, Vinera J1, Zitoun C1, Duchampt A1, Bäckhed F3, Mithieux G4.
Author information
Abstract
Soluble dietary fibers promote metabolic benefits on body weight and glucose control, but underlying mechanisms are poorly understood. Recent evidence indicates that intestinal gluconeogenesis (IGN) has beneficial effects on glucose and energy homeostasis. Here, we show that the short-chain fatty acids (SCFAs) propionate and butyrate, which are generated by fermentation of soluble fiber by the gut microbiota, activate IGN viacomplementary mechanisms. Butyrate activates IGN gene expression through a cAMP-dependent mechanism, while propionate, itself a substrate of IGN, activates IGN gene expression via a gut-brain neural circuit involving the fatty acid receptor FFAR3. The metabolic benefits on body weight and glucose control induced by SCFAs or dietary fiber in normal mice are absent in mice deficient for IGN, despite similar modifications in gut microbiota composition. Thus, the regulation of IGN is necessary for the metabolic benefits associated with SCFAs and soluble fiber.
http://www.ncbi.nlm....pubmed/24388214
Adv Immunol. 2014;121:91-119. doi: 10.1016/B978-0-12-800100-4.00003-9.
The role of short-chain Fatty acids in health and disease.
Tan J1, McKenzie C1, Potamitis M1, Thorburn AN1, Mackay CR2, Macia L3.
Author information
Abstract
There is now an abundance of evidence to show that short-chain fatty acids (SCFAs) play an important role in the maintenance of health and the development of disease. SCFAs are a subset of fatty acids that are produced by the gut microbiota during the fermentation of partially and nondigestible polysaccharides. The highest levels of SCFAs are found in the proximal colon, where they are used locally by enterocytes or transported across the gut epithelium into the bloodstream. Two major SCFA signaling mechanisms have been identified, inhibition of histone deacetylases (HDACs) and activation of G-protein-coupled receptors (GPCRs). Since HDACs regulate gene expression, inhibition of HDACs has a vast array of downstream consequences. Our understanding of SCFA-mediated inhibition of HDACs is still in its infancy. GPCRs, particularly GPR43, GPR41, and GPR109A, have been identified as receptors for SCFAs. Studies have implicated a major role for these GPCRs in the regulation of metabolism, inflammation, and disease. SCFAs have been shown to alter chemotaxis and phagocytosis; induce reactive oxygen species (ROS); change cell proliferation and function; have anti-inflammatory, antitumorigenic, and antimicrobial effects; and alter gut integrity. These findings highlight the role of SCFAs as a major player in maintenance of gut and immune homeostasis. Given the vast effects of SCFAs, and that their levels are regulated by diet, they provide a new basis to explain the increased prevalence of inflammatory disease in Westernized countries, as highlighted in this chapter.
http://www.ncbi.nlm....pubmed/24286462
Genes Brain Behav. 2014 Jan;13(1):69-86. doi: 10.1111/gbb.12109. Epub 2013 Dec 27.
Microbial genes, brain & behaviour - epigenetic regulation of the gut-brain axis.
Stilling RM, Dinan TG, Cryan JF.
Author information
Abstract
To date, there is rapidly increasing evidence for host-microbe interaction at virtually all levels of complexity, ranging from direct cell-to-cell communication to extensive systemic signalling, and involving various organs and organ systems, including the central nervous system. As such, the discovery that differential microbial composition is associated with alterations in behaviour and cognition has significantly contributed to establishing the microbiota-gut-brain axis as an extension of the well-accepted gut-brain axis concept. Many efforts have been focused on delineating a role for this axis in health and disease, ranging from stress-related disorders such as depression, anxiety and irritable bowel syndrome to neurodevelopmental disorders such as autism. There is also a growing appreciation of the role of epigenetic mechanisms in shaping brain and behaviour. However, the role of epigenetics in informing host-microbe interactions has received little attention to date. This is despite the fact that there are many plausible routes of interaction between epigenetic mechanisms and the host-microbiota dialogue. From this new perspective we put forward novel, yet testable, hypotheses. Firstly, we suggest that gut-microbial products can affect chromatin plasticity within their host's brain that in turn leads to changes in neuronal transcription and eventually alters host behaviour. Secondly, we argue that the microbiota is an important mediator of gene-environment interactions. Finally, we reason that the microbiota itself may be viewed as an epigenetic entity. In conclusion, the fields of (neuro)epigenetics and microbiology are converging at many levels and more interdisciplinary studies are necessary to unravel the full range of this interaction.
http://www.ncbi.nlm....pubmed/24332563
Med Hypotheses. 2014 Feb;82(2):163-6. doi: 10.1016/j.mehy.2013.11.026. Epub 2013 Dec 1.
Obsessive-compulsive disorder and gut microbiota dysregulation.
Rees JC.
Author information
Abstract
Obsessive-compulsive disorder (OCD) is a debilitating disorder for which the cause is not known and treatment options are modestly beneficial. A hypothesis is presented wherein the root cause of OCD is proposed to be a dysfunction of the gut microbiome constituency resulting in a susceptibility to obsessional thinking. Both stress and antibiotics are proposed as mechanisms by which gut microbiota are altered preceding the onset of OCD symptomology. In this light, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) leading to episodic OCD is explained not by group A beta-hemolytic streptococcal infections, but rather by prophylactic antibiotics that are administered as treatment. Further, stressful life events known to trigger OCD, such as pregnancy, are recast to show the possibility of altering gut microbiota prior to onset of OCD symptoms. Suggested treatment for OCD would be the directed, specie-specific (re)introduction of beneficial bacteria modifying the gut microbiome, thereby ameliorating OCD symptoms. Special considerations should be contemplated when considering efficacy of treatment, particularly the unhealthy coping strategies often observed in patients with chronic OCD that may need addressing in conjunction with microbiome remediation.
http://www.ncbi.nlm....pubmed/23516017
Cell Mol Life Sci. 2014 Jan;71(2):183-203. doi: 10.1007/s00018-013-1318-0. Epub 2013 Mar 21.
Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective.
Turroni F, Ventura M, Buttó LF, Duranti S, O'Toole PW, Motherway MO, van Sinderen D.
Author information
Abstract
The human gut represents a highly complex ecosystem, which is densely colonized by a myriad of microorganisms that influence the physiology, immune function and health status of the host. Among the many members of the human gut microbiota, there are microorganisms that have co-evolved with their host and that are believed to exert health-promoting or probiotic effects. Probiotic bacteria isolated from the gut and other environments are commercially exploited, and although there is a growing list of health benefits provided by the consumption of such probiotics, their precise mechanisms of action have essentially remained elusive. Genomics approaches have provided exciting new opportunities for the identification of probiotic effector molecules that elicit specific responses to influence the physiology and immune function of their human host. In this review, we describe the current understanding of the intriguing relationships that exist between the human gut and key members of the gut microbiota such as bifidobacteria and lactobacilli, discussed here as prototypical groups of probiotic microorganisms.
http://www.ncbi.nlm....pubmed/23688247
Crit Rev Microbiol. 2014 Aug;40(3):273-80. doi: 10.3109/1040841X.2013.787043. Epub 2013 May 21.
Friendly pathogens: prevent or provoke autoimmunity.
Sathyabama S, Khan N, Agrewala JN.
Author information
Abstract
Abstract The gut microflora is an immense health asset for human beings. The mammalian gut harbors trillions of commensals. These microbes not only modulate local but also systemic immunity. Recently, various reports are evolving, which signify that the gut microbes can modulate, tune and tame the host immune response. Consequently, it advocates the significance of the microbial composition. Further, the microbiota provides a fine equilibrium to host by regulating immune homeostasis. Furthermore, disturbance in this population can incite imbalance in immune system, leading to molecular mimicry and therefore autoimmunity. Hence, it is imperative to understand the influence of these bugs in preventing or provoking immune system against the self-components. In this article, we highlight the interaction between different gut microbes and cells of immune system and the mechanism involved in controlling and curtailing various autoimmune diseases.
http://www.ncbi.nlm....pubmed/24390308
Nat Med. 2014 Jan 5. doi: 10.1038/nm.3444. [Epub ahead of print]
Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis.
Trompette A1, Gollwitzer ES1, Yadava K1, Sichelstiel AK1, Sprenger N2, Ngom-Bru C2, Blanchard C2, Junt T3, Nicod LP1, Harris NL4, Marsland BJ1.
Author information
Abstract
Metabolites from intestinal microbiota are key determinants of host-microbe mutualism and, consequently, the health or disease of the intestinal tract. However, whether such host-microbe crosstalk influences inflammation in peripheral tissues, such as the lung, is poorly understood. We found that dietary fermentable fiber content changed the composition of the gut and lung microbiota, in particular by altering the ratio of Firmicutes to Bacteroidetes. The gut microbiota metabolized the fiber, consequently increasing the concentration of circulating short-chain fatty acids (SCFAs). Mice fed a high-fiber diet had increased circulating levels of SCFAs and were protected against allergic inflammation in the lung, whereas a low-fiber diet decreased levels of SCFAs and increased allergic airway disease. Treatment of mice with the SCFA propionate led to alterations in bone marrow hematopoiesis that were characterized by enhanced generation of macrophage and dendritic cell (DC) precursors and subsequent seeding of the lungs by DCs with high phagocytic capacity but an impaired ability to promote T helper type 2 (TH2) cell effector function. The effects of propionate on allergic inflammation were dependent on G protein-coupled receptor 41 (GPR41, also called free fatty acid receptor 3 or FFAR3), but not GPR43 (also called free fatty acid receptor 2 or FFAR2). Our results show that dietary fermentable fiber and SCFAs can shape the immunological environment in the lung and influence the severity of allergic inflammation.
http://www.ncbi.nlm....pubmed/23703735
Hepatology. 2014 Jan;59(1):328-39. doi: 10.1002/hep.26494. Epub 2013 Nov 15.
Microbiota-liver axis in hepatic disease.
Chassaing B, Etienne-Mesmin L, Gewirtz AT.
Author information
Abstract
Accumulating evidence indicates that the gut microbiota, long appreciated to be a key determinant of intestinal inflammation, is also playing a key role in chronic inflammatory disease of the liver. Such studies have yielded a general central hypothesis whereby microbiota products activate the innate immune system to drive proinflammatory gene expression, thus promoting chronic inflammatory disease of the liver. This article reviews the background supporting this hypothesis, outlines how it can potentially explain classic and newly emerging epidemiological chronic inflammatory liver disease, and discusses potential therapeutic means to manipulate the microbiota so as to prevent and/or treat liver disease. (Hepatology 2014;58:328-339).
http://www.ncbi.nlm....pubmed/23740189
Gut. 2014 Jan;63(1):5-6. doi: 10.1136/gutjnl-2013-304969. Epub 2013 Jun 5.
Western lifestyle: a 'master' manipulator of the intestinal microbiota?
Hold GL.
KEYWORDS:
Diet, Intestinal microbiota
http://www.ncbi.nlm....pubmed/23909466
FEMS Microbiol Ecol. 2014 Jan;87(1):30-40. doi: 10.1111/1574-6941.12186. Epub 2013 Aug 28.
Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro.
Scott KP, Martin JC, Duncan SH, Flint HJ.
Author information
Abstract
Dietary macronutrients affect the composition of the gut microbiota, and prebiotics are used to improve and maintain a healthy gut. The impact of prebiotics on dominant gut bacteria other than bifidobacteria, however, is under-researched. Here, we report carbohydrate utilisation patterns for representative butyrate-producing anaerobes, belonging to the Gram-positive Firmicutes families Lachnospiraceae and Ruminococcaceae, by comparison with selected Bacteroides and Bifidobacterium species. Growth assessments using anaerobic Hungate tubes and a new rapid microtitre plate assay were generally in good agreement. The Bacteroides strains tested showed some growth on basal medium with no added carbohydrates, utilising peptides in the growth medium. The butyrate-producing strains exhibited different growth profiles on the substrates, which included starch, inulin, fructooligosaccharides (FOS), galactooligosaccharides (GOS) and xylooligosaccharides (XOS). Eleven were able to grow on short-chain FOS, but this number decreased as the chain length of the fructan substrates increased. Long-chain inulin was utilised by Roseburia inulinivorans, but by none of the Bifidobacterium species examined here. XOS was a more selective growth substrate than FOS, with only six of the 11 Firmicutes strains able to use XOS for growth. These results illustrate the selectivity of different prebiotics and help to explain why some are butyrogenic.
© 2013 Federation of European Microbiological Societies. Published by John Wiley & Sons Ltd. All rights reserved.
http://www.ncbi.nlm....pubmed/23909489
FEMS Microbiol Ecol. 2014 Jan;87(1):41-51. doi: 10.1111/1574-6941.12187. Epub 2013 Aug 23.
Impact of galacto-oligosaccharides on the gut microbiota composition and metabolic activity upon antibiotic treatment during in vitro fermentation.
Ladirat SE, Schuren FH, Schoterman MH, Nauta A, Gruppen H, Schols HA.
Author information
Abstract
Prebiotics are considered to have potential to reduce disturbances in the gut microbiota induced by antibiotics. Results in literature are, however, not consistent. The current in vitro study conducted in a fermentation screening platform allowed to unambiguously compare the impact of galacto-oligosaccharides (GOS) on adult gut microbiota composition and activity upon treatment with four antibiotics at two doses. The changes in relative abundance of bacteria upon antibiotic treatment and the growth of Bifidobacterium and Lactobacillus upon GOS addition were antibiotic and dose dependant. This conclusion explains discrepancies in literature and indicates that particular combinations of GOS antibiotic should be studied. The combination GOS-Amoxicillin was especially of interest as, after decrease in Bifidobacterium levels, a recovery of mainly Bifidobacterium longum was observed and could be correlated with specific degradation patterns of GOS. Next to different degradation profiles of individual GOS, an accumulation of monosaccharides and intermediate organic acids was observed in antibiotic-treated microbiota as compared to nontreated microbiota. This showed that although GOS were utilized and beneficial bacteria could grow in 3 of 4 antibiotics tested, the metabolic activity of an antibiotic-treated microbiota was still disturbed as compared to the nontreated microbiota.
http://www.ncbi.nlm....pubmed/23829297
J Gastroenterol Hepatol. 2014 Jan;29(1):52-9. doi: 10.1111/jgh.12322.
Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial.
Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG.
Author information
Abstract
BACKGROUND AND AIM:
The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms and the alterations of gut microbiota in patients who have taken probiotics were investigated.
METHODS:
This randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multispecies probiotics (a mixture of Bifidobacterium longum, B. bifidum, B. lactis, Lactobacillus acidophilus, L. rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks or to receive a placebo twice a day for 4 weeks. The primary efficacy end-point was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary end-points were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the 4 weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time polymerase chain reaction assays.
RESULTS:
The proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25) versus 37.5% (9/24) (P < 0.05). Secondary end-points such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B. lactis, L. rhamnosus, and S. thermophilus had increased significantly in the probiotics group after 4 weeks and that B. lactis had increased in the placebo group.
CONCLUSIONS:
Multispecies probiotics are effective in IBS patients and induce the alterations in the composition of intestinal microbiota.
http://www.ncbi.nlm....pubmed/23941288
Int J Food Sci Nutr. 2014 Feb;65(1):79-88. doi: 10.3109/09637486.2013.825700. Epub 2013 Aug 13.
In vitro batch cultures of gut microbiota from healthy and ulcerative colitis (UC) subjects suggest that sulphate-reducing bacteria levels are raised in UC and by a protein-rich diet.
Khalil NA, Walton GE, Gibson GR, Tuohy KM, Andrews SC.
Author information
Abstract
Abstract Imbalances in gut microbiota composition during ulcerative colitis (UC) indicate a role for the microbiota in propagating the disorder. Such effects were investigated using in vitro batch cultures (with/without mucin, peptone or starch) inoculated with faecal slurries from healthy or UC patients; the growth of five bacterial groups was monitored along with short-chain fatty acid (SCFA) production. Healthy cultures gave two-fold higher growth and SCFA levels with up to ten-fold higher butyrate production. Starch gave the highest growth and SCFA production (particularly butyrate), indicating starch-enhanced saccharolytic activity. Sulphate-reducing bacteria (SRB) were the predominant bacterial group (of five examined) for UC inocula whereas they were the minority group for the healthy inocula. Furthermore, SRB growth was stimulated by peptone presumably due to the presence of sulphur-rich amino acids. The results suggest raised SRB levels in UC, which could contribute to the condition through release of toxic sulphide.
http://www.ncbi.nlm....pubmed/24322902
Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):1. doi: 10.1038/nrgastro.2013.238. Epub 2013 Dec 10.
Gut microbiota: Anti-cancer therapies affected by gut microbiota.
Greenhill C.
http://www.ncbi.nlm....pubmed/24296462
Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):15-21. doi: 10.1097/MED.0000000000000032.
Irritable bowel syndrome, inflammatory bowel disease and the microbiome.
Major G, Spiller R.
Author information
Abstract
PURPOSE OF REVIEW:
The review aims to update the reader on current developments in our understanding of how the gut microbiota impact on inflammatory bowel disease and the irritable bowel syndrome. It will also consider current efforts to modulate the microbiota for therapeutic effect.
RECENT FINDINGS:
Gene polymorphisms associated with inflammatory bowel disease increasingly suggest that interaction with the microbiota drives pathogenesis. This may be through modulation of the immune response, mucosal permeability or the products of microbial metabolism. Similar findings in irritable bowel syndrome have reinforced the role of gut-specific factors in this 'functional' disorder. Metagenomic analysis has identified alterations in pathways and interactions with the ecosystem of the microbiome that may not be recognized by taxonomic description alone, particularly in carbohydrate metabolism. Treatments targeted at the microbial stimulus with antibiotics, probiotics or prebiotics have all progressed in the past year. Studies on the long-term effects of treatment on the microbiome suggest that dietary intervention may be needed for prolonged efficacy.
SUMMARY:
The microbiome represents 'the other genome', and to appreciate its role in health and disease will be as challenging as with our own genome. Intestinal diseases occur at the front line of our interaction with the microbiome and their future treatment will be shaped as we unravel our relationship with it.
http://www.ncbi.nlm....pubmed/24287935
Appl Microbiol Biotechnol. 2014 Jan;98(2):563-77. doi: 10.1007/s00253-013-5405-9. Epub 2013 Nov 28.
Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants.
Di Gioia D, Aloisio I, Mazzola G, Biavati B.
Author information
Abstract
This review is aimed at describing the most recent advances in the gut microbiota composition of newborns and infants with a particular emphasis on bifidobacteria. The newborn gut microbiota is quite unstable, whereas after weaning, it becomes more stable and gets closer to the typical adult microbiota. The newborn and infant gut microbiota composition is impaired in several enteric and non-enteric pathologies. The core of this review is the description of the most recent documented applications of bifidobacteria to newborns and infants for their prevention and treatment. Acute diarrhea is the most studied disease for which bifidobacteria are applied with great success, Bifidobacterium longum and Bifidobacterium breve being the most applied species. Moreover, the most recent updates in the use of bifidobacteria for the prevention and treatment of pathologies typical of newborns, such as necrotizing enterocolitis, colics, and streptococcal infections, are presented. In addition, a number of not strictly enteric pathologies have in recent years evidenced a strict correlation with an aberrant gut microbiota in infants, in particular showing a reduced level of bifidobacteria. These diseases represent new potential opportunities for probiotic applications. Among them, allergic diseases, celiac disease, obesity, and neurologic diseases are described in this review. The preliminary use of bifidobacteria in in vitro systems and animal models is summarized as well as preliminary in vivo studies. Only after validation of the results via human clinical trials will the potentiality of bifidobacteria in the prevention and cure of these pathologies be definitely assessed.
http://www.ncbi.nlm....pubmed/24274865
Clin Liver Dis. 2014 Feb;18(1):59-71. doi: 10.1016/j.cld.2013.09.002. Epub 2013 Oct 24.
Obesity and NAFLD: The role of bacteria and microbiota.
Duseja A, Chawla YK.
Author information
Abstract
There are trillions of microorganisms in the human intestine collectively called gut microbiota. Obesity may be affected by the gut microbiota through energy harvesting and fat storage by the bacteria. Small intestinal bacterial overgrowth is also responsible for endotoxemia, systemic inflammation, and its consequences including obesity and nonalcoholic fatty liver disease (NAFLD). Relationship between gut microbiota and NAFLD is also dependent on altered choline and bile acid metabolism and endogenous alcohol production by gut bacteria. Further evidence linking gut microbiota with obesity and NAFLD comes from studies showing usefulness of probiotics in animals and patients with NAFLD. This article reviews the relationship among gut microbiota, obesity, and NAFLD.
http://www.ncbi.nlm....pubmed/24165893
Cell Res. 2014 Jan;24(1):5-6. doi: 10.1038/cr.2013.142. Epub 2013 Oct 29.
An antibiotic-altered microbiota provides fuel for the enteric foe.
Stiemsma LT1, Turvey SE2, Finlay BB1.
Author information
Abstract
Antibiotic therapies disrupt the intestinal microbiota and render the host susceptible to enteric infections. A recent report by Ng et al. explores the ability of two intestinal pathogens (Salmonella enterica serovar Typhimurium and Clostridium difficile) to use this disruption to their advantage and consume host carbohydrates that would otherwise be unavailable in the presence of a normal gut microbiota.
http://www.ncbi.nlm....pubmed/24123746
Appl Environ Microbiol. 2014 Jan;80(1):9-18. doi: 10.1128/AEM.02977-13. Epub 2013 Oct 11.
Genomic Overview and Biological Functions of Exopolysaccharide Biosynthesis in Bifidobacterium spp.
Hidalgo-Cantabrana C, Sánchez B, Milani C, Ventura M, Margolles A, Ruas-Madiedo P.
Author information
Abstract
For many years, bacterial exopolysaccharides (EPS) have received considerable scientific attention, mainly due to their contribution to biofilm formation and, above all, because EPS are potential virulence factors. In recent times, interest in EPS research has enjoyed a welcome boost thanks to the discovery of their ability to mediate communication processes with their surrounding environment and to their contribution to host health maintenance. In this review, we provide a fresh perspective on the genetics and activity of these polymers in members of the Bifidobacterium genus, a common gut inhabitant of humans and animals that has been associated with several health-promoting effects. Bifidobacteria can use EPS to protect themselves against the harsh conditions of the gastrointestinal tract, thus improving their persistence in the host. Indeed, the relevant function of EPS for bifidobacteria is underlined by the fact that most genomes sequenced until now contain genes related to EPS biosynthesis. A high interspecies variability in the number of genes and structural organization is denoted among species/subspecies; thus, eps clusters in this genus do not display a consensus genetic architecture. Their different G+C content compared to that of the whole genome suggests that eps genes have been acquired by horizontal transfer. From the host perspective, EPS-producing bifidobacteria are able to trigger both innate and adaptive immune responses, and they are able to modulate the composition and activity of the gut microbiota. Thus, these polymers seem to be critical in understanding the physiology of bifidobacteria and their interaction with the host.
http://www.ncbi.nlm....pubmed/24114492
Cancer Treat Res. 2014;159:377-99. doi: 10.1007/978-3-642-38007-5_22.
Gut microbes, diet, and cancer.
Hullar MA, Burnett-Hartman AN, Lampe JW.
Author information
Abstract
An expanding body of evidence supports a role for gut microbes in the etiology of cancer. Previously, the focus was on identifying individual bacterial species that directly initiate or promote gastrointestinal malignancies; however, the capacity of gut microbes to influence systemic inflammation and other downstream pathways suggests that the gut microbial community may also affect risk of cancer in tissues outside of the gastrointestinal tract. Functional contributions of the gut microbiota that may influence cancer susceptibility in the broad sense include (1) harvesting otherwise inaccessible nutrients and/or sources of energy from the diet (i.e., fermentation of dietary fibers and resistant starch); (2) metabolism of xenobiotics, both potentially beneficial or detrimental (i.e., dietary constituents, drugs, carcinogens, etc.); (3) renewal of gut epithelial cells and maintenance of mucosal integrity; and (4) affecting immune system development and activity. Understanding the complex and dynamic interplay between the gut microbiome, host immune system, and dietary exposures may help elucidate mechanisms for carcinogenesis and guide future cancer prevention and treatment strategies.
http://www.ncbi.nlm....pubmed/24399149
Mucosal Immunol. 2014 Jan 8. doi: 10.1038/mi.2013.117. [Epub ahead of print]
Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns.
Pamer EG.
Author information
Abstract
The mammalian colon is home to a microbial ecosystem that enhances resistance to infection, stimulates mucosal immune defenses, synthesizes essential vitamins, and promotes caloric uptake by hydrolyzing complex carbohydrates. The bacterial populations inhabiting the gut are complex and vary between different individuals. Clinical and experimental studies reveal that the colonic microbiota can enhance or ameliorate intestinal and systemic inflammatory diseases. Because of its potential to enhance resistance to infection and to reduce inflammatory diseases, targeted manipulation of microbial populations is a growing focus of investigation. The most dramatic manipulation of the intestinal microbiota involves fecal microbiota transplantation (FMT) from healthy donors to individuals with specific diseases. Remarkable clinical effectiveness of FMT has been demonstrated for recurrent Clostridium difficile infection and ongoing studies are investigating FMT for other diseases. Transplantation of complex microbial populations to recipients likely triggers mucosal immune responses that, depending on the microbiota composition and the recipient's genotype, could range from pro- to anti-inflammatory. The impact of FMT on the recipient immune system is complex and unpredictable. Ongoing discovery of commensal microbes and investigations of their impact on the host will lead to the development of new probiotic agents and microbial consortia that will eventually replace FMT.Mucosal Immunology advance online publication, 8 January 2014. doi:10.1038/mi.2013.117.
http://www.ncbi.nlm....pubmed/24390924
Semin Reprod Med. 2014 Jan;32(1):74-86. doi: 10.1055/s-0033-1361825. Epub 2014 Jan 3.
Early development of the gut microbiome and immune-mediated childhood disorders.
Li M, Wang M, Donovan SM.
Author information
Abstract
The human gastrointestinal tract inhabits a complex microbial ecosystem that plays a vital role in host health through its contributions to nutrient synthesis and digestion, protection from pathogens, and promoting maturation of host innate and adapt immune systems. The development of gut microbiota primarily occurs during infancy and is influenced by multiple factors, including prenatal exposure; gestational age; mode of delivery; feeding type; pre-, pro-, and antibiotic use; and host genetics. In genetically susceptible individuals, changes in the gut microbiota induced by environmental factors may contribute to the development of immune-related disorders in childhood, including atopic diseases, inflammatory bowel disease, irritable bowel syndrome, and necrotizing enterocolitis. Pre- and probiotics may be useful in the prevention and treatment of some immune-related diseases by modulating gut microbiota and regulating host mucosal immune function. The review will discuss recent findings on the environmental factors that influence development of gut microbiota during infancy and its potential impact on some immune-related diseases in childhood. The use of pre- and probiotics for prevention and intervention of several important diseases in early life will also be reviewed.
http://www.ncbi.nlm....pubmed/24390923
Semin Reprod Med. 2014 Jan;32(1):68-73. doi: 10.1055/s-0033-1361824. Epub 2014 Jan 3.
A review of the source and function of microbiota in breast milk.
Latuga MS1, Stuebe A2, Seed PC3.
Author information
Abstract
Breast milk contains a rich microbiota composed of viable skin and non-skin bacteria. The extent of the breast milk microbiota diversity has been revealed through new culture-independent studies using microbial DNA signatures. However, the extent to which the breast milk microbiota are transferred from mother to infant and the function of these breast milk microbiota for the infant are only partially understood. Here, we appraise hypotheses regarding the formation of breast milk microbiota, including retrograde infant-to-mother transfer and enteromammary trafficking, and we review current knowledge of mechanisms determining the extent of breast milk microbiota transfer from mother to infant. We highlight known functions of constituents in the breast milk microbiota-to enhance immunity, liberate nutrients, synergize with breast milk oligosaccharides to enhance intestinal barrier function, and strengthen a functional gut-brain axis. We also consider the pathophysiology of maternal mastitis with respect to a dysbiosis or abnormal shift in the breast milk microbiota. In conclusion, through a complex, highly evolved process in the early stages of discovery, mothers transfer the breast milk microbiota to their infants to impact infant growth and development.
http://www.ncbi.nlm....pubmed/24388028
Mayo Clin Proc. 2014 Jan;89(1):107-14. doi: 10.1016/j.mayocp.2013.10.011.
A Clinician's Primer on the Role of the Microbiome in Human Health and Disease.
Khanna S1, Tosh PK2.
Author information
Abstract
The importance of the commensal microbiota that colonizes the skin, gut, and mucosal surfaces of the human body is being increasingly recognized through a rapidly expanding body of science studying the human microbiome. Although, at first glance, these discoveries may seem esoteric, the clinical implications of the microbiome in human health and disease are becoming clear. As such, it will soon be important for practicing clinicians to have an understanding of the basic concepts of the human microbiome and its relation to human health and disease. In this Concise Review, we provide a brief introduction to clinicians of the concepts underlying this burgeoning scientific field and briefly explore specific disease states for which the potential role of the human microbiome is becoming increasingly evident, including Clostridium difficile infection, inflammatory bowel disease, colonization with multidrug-resistant organisms, obesity, allergic diseases, autoimmune diseases, and neuropsychiatric illnesses, and we also discuss current and future roles of microbiome restorative therapies.
http://www.ncbi.nlm....pubmed/24328376
Future Microbiol. 2014 Jan;9:13-6. doi: 10.2217/fmb.13.141.
How enteric pathogens know they hit the sweet spot.
Alvarado I, Abel-Santos E.
Author information
Abstract
EVALUATION OF:
Ng KM, Ferreyra JA, Higginbottom SK et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502(7469), 96-99 (2013). The human gut microbiota is a complex system of commensal microorganisms required for normal host physiology. Disruption of this protective barrier by antibiotics creates opportunities for enteric pathogens to establish infections. Although the correlation between the use of antibiotics and enteric infections have been known for some time, the specific signals that allow enteric pathogens to recognize a susceptible host have not been determined. In a recent article, Ng et al. demonstrated that the expansion of both Salmonella typhimurium and Clostridium difficile infections is enhanced by the availability of host-specific sugars liberated from the intestinal mucus by commensal bacteria. These results show how antibiotic removal of specific species from the gut microbiome allows symbiotic functions to be hijacked by pathogenic species.
http://www.ncbi.nlm....pubmed/24382146
Br J Nutr. 2014 Jan 2:1-6. [Epub ahead of print]
Dietary supplementation with lactose or artificial sweetener enhances swine gut Lactobacillus population abundance.
Daly K1, Darby AC1, Hall N1, Nau A2, Bravo D2, Shirazi-Beechey SP1.
Author information
Abstract
The commensal bacteria Lactobacillus are widely used as probiotic organisms conferring a heath benefit on the host. They have been implicated in promoting gut health via the stimulation of host immunity and anti-inflammatory responses, as well as protecting the intestinalmucosa against pathogen invasion. Lactobacilli grow by fermenting sugars and starches and produce lactic acid as their primary metabolic product. For efficient utilisation of varied carbohydrates, lactobacilli have evolved diverse sugar transport and metabolic systems, which are specifically induced by their own substrates. Many bacteria are also capable of sensing and responding to changes in their environment. These sensory responses are often independent of transport or metabolism and are mediated through membrane-spanning receptor proteins. We employed DNA-based pyrosequencing technology to investigate the changes in the intestinal microbiota of piglets weaned to a diet supplemented with either a natural sugar, lactose or an artificial sweetener (SUCRAM®, consisting of saccharin and neohesperidin dihydrochalcone (NHDC); Pancosma SA). The addition of either lactose or saccharin/NHDC to the piglets' feed dramatically increased the caecal population abundance of Lactobacillus, with concomitant increases in intraluminal lactic acid concentrations. This is the first report of the prebiotic-like effects of saccharin/NHDC, an artificial sweetener, being able to influence the commensal gut microbiota. The identification of the underlying mechanism(s) will assist in designing nutritional strategies for enhancing gut immunity and maintaining gut health.
http://www.ncbi.nlm....pubmed/24389673
Curr Opin Clin Nutr Metab Care. 2014 Jan 2. [Epub ahead of print]
Biological significance of short-chain fatty acid metabolism by the intestinal microbiome.
Puertollano E, Kolida S, Yaqoob P.
Author information
Abstract
PURPOSE OF REVIEW:
Evidence suggests that short-chain fatty acids (SCFAs) derived from microbial metabolism in the gut play a central role in host homeostasis. The present review describes the current understanding and physiological implications of SCFAs derived from microbial metabolism of nondigestible carbohydrates.
RECENT FINDINGS:
Recent studies indicate a role for SCFAs, in particular propionate and butyrate, in metabolic and inflammatory disorders such as obesity, diabetes and inflammatory bowel diseases, through the activation of specific G-protein-coupled receptors and modification of transcription factors. Established prebiotics, such as fructooligosaccharides and galactooligosaccharides, which support the growth of Bifidobacteria, mainly mediate acetate production. Thus, recent identification of prebiotics which are able to stimulate the production of propionate and butyrate by benign saccharolytic populations in the colon is of interest.
SUMMARY:
Manipulation of saccharolytic fermentation by prebiotic substrates is beginning to provide information on structure-function relationships relating to the production of SCFAs, which have multiple roles in host homeostasis.
http://www.ncbi.nlm....pubmed/24332541
Curr Biol. 2014 Jan 6;24(1):40-9. doi: 10.1016/j.cub.2013.10.077. Epub 2013 Dec 12.
An Ecological Network of Polysaccharide Utilization among Human Intestinal Symbionts.
Rakoff-Nahoum S1, Coyne MJ2, Comstock LE3.
Author information
Abstract
BACKGROUND:
The human intestine is colonized with trillions of microorganisms important to health and disease. There has been an intensive effort to catalog the species and genetic content of this microbial ecosystem. However, little is known of the ecological interactions between these microbes, a prerequisite to understanding the dynamics and stability of this host-associated microbial community. Here we perform a systematic investigation of public goods-based syntrophic interactions among the abundant human gut bacteria, the Bacteroidales.
RESULTS:
We find evidence for a rich interaction network based on the breakdown and use of polysaccharides. Species that utilize a particular polysaccharide (producers) liberate polysaccharide breakdown products (PBPs) that are consumed by other species unable to grow on the polysaccharide alone (recipients). Cross-species gene addition experiments demonstrate that recipients can grow on a polysaccharide if the producer-derived glycoside hydrolase, responsible for PBP generation, is provided. These producer-derived glycoside hydrolases are public goods transported extracellularly in outer membrane vesicles allowing for the creation of PBP and concomitant recipient growth spatially distant from the producer. Recipients can exploit these ecological interactions and conditionally outgrow producers. Finally, we show that these public goods-based interactions occur among Bacteroidales species coresident within a natural human intestinal community.
CONCLUSIONS:
This study examines public goods-based syntrophic interactions between bacterial members of the human gut microbial ecosystem. This polysaccharide-based network likely represents foundational relationships creating organized ecological units within the intestinal microbiota, knowledge of which can be applied to impact human health.
http://www.ncbi.nlm....pubmed/24355793
J Nutr Biochem. 2013 Oct 29. pii: S0955-2863(13)00210-6. doi: 10.1016/j.jnutbio.2013.09.009. [Epub ahead of print]
Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes.
Shen W1, Gaskins HR2, McIntosh MK3.
Author information
Abstract
Recent studies using germ-free, gnotobiotic microbial transplantation/conventionalization or antibiotic treatment in rodent models have highlighted the critical role of intestinal microbes on gut health and metabolic functions of the host. Genetic and environmental factors influence the abundance and type of mutualistic vs. pathogenic bacteria, each of which has preferred substrates for growth and unique products of fermentation. Whereas some fermentation products or metabolites promote gut function and health, others impair gut function, leading to compromised nutrient digestion and barrier function that adversely impact the host. Such products may also influence food intake, energy harvest and expenditure, and insulin action, thereby influencing adiposity and related metabolic outcomes. Diet composition influences gut microbiota and subsequent fermentation products that impact the host, as demonstrated by prebiotic studies using oligosaccharides or other types of indigestible fiber. Recent studies also show that dietary lipids affect specific populations of gut microbes and their metabolic end products. This review will focus on studies examining the influence of dietary fat amount and type on the gut microbiome, intestinal health and positive and negative metabolic consequences. The protective role of omega-3-rich fatty acids on intestinal inflammation will also be examined.
http://www.ncbi.nlm....pubmed/24314205
J Appl Microbiol. 2013 Dec 7. doi: 10.1111/jam.12415. [Epub ahead of print]
Summer Meeting 2013: growth and physiology of bifidobacteria.
De Vuyst L, Moens F, Selak M, Rivière A, Leroy F.
Author information
Abstract
Bifidobacteria are a minor fraction of the human colon microbiota with interesting properties for carbohydrate degradation. Monosaccharides such as glucose and fructose are degraded through the bifid shunt, a dedicated pathway involving phosphoketolase activity. Its stoechiometry learns that three moles of acetate and two moles of lactate are produced per two moles of glucose or fructose that are degraded. However, deviations from this 3 : 2 ratio occur, depending on the rate of substrate consumption. Slower growth rates favour the production of acetate and pyruvate catabolites (such as formate) at the cost of lactate. Interestingly, bifidobacteria are capable to degrade inulin-type fructans (ITF) (oligofructose and inulin) and arabinoxylan-oligosaccharides (AXOS). Beta-fructofuranosidase activity enables bifidobacteria to degrade ITF. However, this property is strain-dependent. Some strains consume both fructose and oligofructose, with different preferences and degradation rates. Small oligosaccharides (degree of polymerization or DP of 2-7) are taken up, in a sequential order, indicating intracellular degradation and as such giving these bacteria a competitive advantage towards other inulin-type fructan degraders such as lactobacilli, bacteroides and roseburias. Other strains consume long fractions of oligofructose and inulin. Exceptionally, oligosaccharides with a DP of up to 20 (long-chain inulin) are consumed by specific strains. Also, the degradation of AXOS by α-arabinofuranosidase and β-xylosidase is strain-dependent. Particular strains consume the arabinose substituents, whether or not together with a consumption of the xylose backbones of AXOS, either up to xylotetraose or higher and either extra- or intracellularly. The production of high amounts of acetate that accompanies inulin-type fructan degradation by bifidobacteria cross-feeds other colon bacteria involved in the production of butyrate. However, bifidobacterial strain-dependent differences in prebiotic degradation indicate the existence of niche-specific adaptations and hence mechanisms to avoid competition among each other and to favour coexistence with other colon bacteria.
http://www.ncbi.nlm....les/PMC3705355/
Nutrients. 2013 Apr 22;5(4):1417-35. doi: 10.3390/nu5041417.
Fiber and prebiotics: mechanisms and health benefits.
Slavin J.
Author information
Abstract
The health benefits of dietary fiber have long been appreciated. Higher intakes of dietary fiber are linked to less cardiovascular disease and fiber plays a role in gut health, with many effective laxatives actually isolated fiber sources. Higher intakes of fiber are linked to lower body weights. Only polysaccharides were included in dietary fiber originally, but more recent definitions have included oligosaccharides as dietary fiber, not based on their chemical measurement as dietary fiber by the accepted total dietary fiber (TDF) method, but on their physiological effects. Inulin, fructo-oligosaccharides, and other oligosaccharides are included as fiber in food labels in the US. Additionally, oligosaccharides are the best known "prebiotics", "a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host well-bring and health." To date, all known and suspected prebiotics are carbohydrate compounds, primarily oligosaccharides, known to resist digestion in the human small intestine and reach the colon where they are fermented by the gut microflora. Studies have provided evidence that inulin and oligofructose (OF), lactulose, and resistant starch (RS) meet all aspects of the definition, including the stimulation of Bifidobacterium, a beneficial bacterial genus. Other isolated carbohydrates and carbohydrate-containing foods, including galactooligosaccharides (GOS), transgalactooligosaccharides (TOS), polydextrose, wheat dextrin, acacia gum, psyllium, banana, whole grain wheat, and whole grain corn also have prebiotic effects.
Edited by lostfalco, 29 January 2014 - 03:51 PM.
Posted 29 January 2014 - 03:23 PM
Yeah, I think we totally agree here Nattzor. We may just differ a little on 'order of operations'. I'd simply say try prebiotics first and if that works, then no need to add probiotics. That's all. I think otherwise, we completely agree.Just to clarify...I'm recommending PREbiotics first. Prebiotics = food for good bacteria. Probiotics = good bacteria themselves. I think that most people already have the good bacteria, they just need to feed them (obviously, there will be exceptions). In most cases, probiotics are probably unnecessary. =)
I'll post abstracts to all of the 2014 studies that I'm currently going through in another post. Give me just one minute....
I'd recommend both instead. There is tons of research on individual strains (everything from making rats "glow" of health/beauty, curing Crohn's (well, that's mainly poop) to less bodyfat and better blood profiles), probiotic meals (kefir, sauerkraut, etc), all showing vert promising results. I'm guessing, due to the hygiene standards we have today, we've fucked up most of the bacterias we have. Introducing more ("good") strains when also adding prebiotics to help them, and the others, survive will most likely produce the best results.
Posted 29 January 2014 - 05:20 PM
I just bought a bottle of this stuff from amazon:
http://www.amazon.co...0?ie=UTF8&psc=1
Started adding a tbsp of potato starch to my morning soylent.
http://quackfiles.bl...cs-warning.html
I questioned numerous respected naturopaths, microbiology professors and gastroenterologists for their opinion on the product and all said it looked fine.
Posted 29 January 2014 - 05:35 PM
Posted 29 January 2014 - 06:26 PM
Posted 29 January 2014 - 09:27 PM
Posted 29 January 2014 - 10:46 PM
Posted 30 January 2014 - 05:32 AM
I've had good results with only O2. If you look at the studies, its primary nootropic effect is mostly evident during high mental exertion. Although, it does seem to help at other times as well.There are several supplemental O2 products such as Boost Oxygen that are readily available at Walmart. That being said there are many consumer reviews of these products. It seems under normal breathing conditions these people do not feel any significant nootropic effect but I saw a body builder review saying it helps replenish her when oxygen starved from continuous hard workouts so she can continue.
The nootropic effect of supplemental oxygen by itself seems insignificant to reviewers. But I would urge someone to try it in combination with the potent vasodilator properties of Vitamin B3 (niacin). I have read that some blood vessels in the brain are so small blood cells travel through in single file. To enhance the reach of the O2, perhaps combination with a vasodilator to deliver oxygen to oxygen starved parts of the brain may enhance the effects.
With that said, the vasodilator idea is right on in my experience. I've combined O2 with a vibration plate...which makes me feel incredible. I've also used O2 with the laser (it's a vasodilator), vinpocetine, nicergoline, and combos of all of the above. Huge energy boost for hours.
Posted 30 January 2014 - 05:37 AM
Hey guys ! just wanted to share with you the amazing change I'm experiencing with the LLLT.
I'm doing LLLT for around 3 month now- and the results keep amaze me. I didn't really realize how
Significant they actually were until today evening- as we had a social event and I meet a couple of guys
That I talk with a week ago.. and not only I remember all the names perfectly- but I recall exactly what this
person has told me, what he was specialized in and when he did it. As the conversations went on-
I felt unbelievable.My brain spit out every piece of information about this specific specialization with
the person with whom I talked to.. and it wasn't little. Soon people start to gather around.. I was kind of
afraid of that as I never use to be in the center of conversation- but I couldn't help it- the conversation
flow so smoothly as my brain connect the dots for me before I even realize that. And all the mentioned
has happened in a language that is not my native language, which makes it even more remarkable.
That being said- it took me some time to tune-up the LLLT routine, it's ongoing process . However, so far
the modification I did to the TULIP protocol are these :
[ all these ingredients were deeply researched beforehand. But more importantly, I've figure out the optimal dosage,
way of administration and optimal time of consumption according to the pharmacokinetics propeties of the substances. ]
[ only in days of LLLT ]
- 5g curcumine + 2g black pepper - both need to be dissolved in oil. preferably olive oil or fish oil
- 2g cinnamon - Need to be dissolved with a little hot water, and let sit for a while.
- 20 drops of diluted Methylene blue
- 10mg noopept
- 60mg Ginkgo Biloba ( pill )
- 200mg CoQ 10 ( pill )
All this need to be taken 1.5 - 2 hours before the LLLT treatment, as this is the peak concentration in the blood
of most of the mentioned agents.
All these agents are basically serve for their neuro-protective properties, that literally `buy some time` ,in order to prolong the time-per-spot
Posted 30 January 2014 - 03:47 PM
Hey middpanther!The studies are great and all, but has anyone actually tried the potato starch/prebiotics?
Edited by lostfalco, 30 January 2014 - 03:50 PM.
Posted 30 January 2014 - 06:56 PM
Hey guys ! just wanted to share with you the amazing change I'm experiencing with the LLLT.
I'm doing LLLT for around 3 month now- and the results keep amaze me. I didn't really realize how
Significant they actually were until today evening- as we had a social event and I meet a couple of guys
That I talk with a week ago.. and not only I remember all the names perfectly- but I recall exactly what this
person has told me, what he was specialized in and when he did it. As the conversations went on-
I felt unbelievable.My brain spit out every piece of information about this specific specialization with
the person with whom I talked to.. and it wasn't little. Soon people start to gather around.. I was kind of
afraid of that as I never use to be in the center of conversation- but I couldn't help it- the conversation
flow so smoothly as my brain connect the dots for me before I even realize that. And all the mentioned
has happened in a language that is not my native language, which makes it even more remarkable.
That being said- it took me some time to tune-up the LLLT routine, it's ongoing process . However, so far
the modification I did to the TULIP protocol are these :
[ all these ingredients were deeply researched beforehand. But more importantly, I've figure out the optimal dosage,
way of administration and optimal time of consumption according to the pharmacokinetics propeties of the substances. ]
[ only in days of LLLT ]
- 5g curcumine + 2g black pepper - both need to be dissolved in oil. preferably olive oil or fish oil
- 2g cinnamon - Need to be dissolved with a little hot water, and let sit for a while.
- 20 drops of diluted Methylene blue
- 10mg noopept
- 60mg Ginkgo Biloba ( pill )
- 200mg CoQ 10 ( pill )
All this need to be taken 1.5 - 2 hours before the LLLT treatment, as this is the peak concentration in the blood
of most of the mentioned agents.
All these agents are basically serve for their neuro-protective properties, that literally `buy some time` ,in order to prolong the time-per-spot
LED or Vetro?
Posted 30 January 2014 - 10:59 PM
Posted 31 January 2014 - 03:22 AM
Posted 31 January 2014 - 03:38 AM
Posted 31 January 2014 - 05:30 PM
Posted 01 February 2014 - 03:57 PM
Edited by lostfalco, 01 February 2014 - 03:58 PM.
Posted 01 February 2014 - 07:48 PM
Edited by OpaqueMind, 01 February 2014 - 08:05 PM.
Posted 01 February 2014 - 08:12 PM
Edited by macropsia, 01 February 2014 - 08:14 PM.
Posted 01 February 2014 - 08:33 PM
That's a great point Opaque. This microflora topic is huge and pretty revolutionary as you said. I've already started 5 threads...I guess one more won't hurt. haEDIT; I feel like this topic deserves it's own thread. It seems to me that the sheer mishmash of topics in this thread is a detriment to proper information gathering :(
Posted 01 February 2014 - 09:36 PM
Yours and Opaque's wishes are my command. I'm shooting for the Longecity record for most threads started. =) http://www.longecity...in-enhancement/edit: I certainly second Opaque's suggestion. It's already impossible to find anything in this thread lol.
Posted 01 February 2014 - 10:04 PM
Edited by Joe Cohen, 01 February 2014 - 10:05 PM.
Posted 02 February 2014 - 10:22 PM
Edited by Joe Cohen, 02 February 2014 - 10:45 PM.
Posted 02 February 2014 - 10:57 PM
Thanks man!LF, I published your collation of the studies. Thanks. http://selfhacked.co...iet-is-healthy/
I gave you credit at the end. Not sure how you want to be referenced.
Btw, have you experimented with kombucha?
Thanks for the heads up Joe! I know you're way ahead of the curve on this. Have you tried XOS?Effect of honey on the growth of and acid production by human intestinal Bifidobacterium spp.: an in vitro comparison with commercial oligosaccharides and inulin.
"Five human intestinal Bifidobacterium spp., B. longum, B. adolescentis, B. breve, B. bifidum, and B. infantis, were cultured..... Honey enhanced the growth of the five cultures much like FOS, GOS, and inulin did. Honey, FOS, GOS, and inulin were especially effective (P < 0.05) in sustaining the growth of these cultures after 24 h of incubation as compared with the control treatment. Overall, the effects of honey on lactic and acetic acid production by intestinal Bifidobacterium spp. were similar to those of FOS, GOS, and inulin."
I've been selfhacking with honey for years to improve cognitive performance, with good effect. Fructose doesn't go well with a high fat diet in my experience. Honey is advantageous to FOS, GOS and inulin in that it ALSO has powerful antimicrobial properties that kill negative bacteria in the gut. MUST BE RAW.
I have some honey's that I like best in my toolkit, but you are welcome to try your own honeys
Posted 02 February 2014 - 11:53 PM
Thanks man!LF, I published your collation of the studies. Thanks. http://selfhacked.co...iet-is-healthy/
I gave you credit at the end. Not sure how you want to be referenced.
Btw, have you experimented with kombucha?
I've looked into it but haven't tried it yet. Just being cautious since a handful of people have had serious problems with it. Def gonna try it soon though.Thanks for the heads up Joe! I know you're way ahead of the curve on this. Have you tried XOS?Effect of honey on the growth of and acid production by human intestinal Bifidobacterium spp.: an in vitro comparison with commercial oligosaccharides and inulin.
"Five human intestinal Bifidobacterium spp., B. longum, B. adolescentis, B. breve, B. bifidum, and B. infantis, were cultured..... Honey enhanced the growth of the five cultures much like FOS, GOS, and inulin did. Honey, FOS, GOS, and inulin were especially effective (P < 0.05) in sustaining the growth of these cultures after 24 h of incubation as compared with the control treatment. Overall, the effects of honey on lactic and acetic acid production by intestinal Bifidobacterium spp. were similar to those of FOS, GOS, and inulin."
I've been selfhacking with honey for years to improve cognitive performance, with good effect. Fructose doesn't go well with a high fat diet in my experience. Honey is advantageous to FOS, GOS and inulin in that it ALSO has powerful antimicrobial properties that kill negative bacteria in the gut. MUST BE RAW.
I have some honey's that I like best in my toolkit, but you are welcome to try your own honeys
Edited by Joe Cohen, 02 February 2014 - 11:56 PM.
Posted 03 February 2014 - 02:37 AM
Posted 03 February 2014 - 05:40 AM
Posted 03 February 2014 - 06:46 PM
Edited by basicallyyes, 03 February 2014 - 06:58 PM.
Science & Health →
Brain Health →
Nootropic Stacks →
how would you describe Cerebrolysin to a person unfamiliar to nootropics?Started by davidwood557 , 01 Oct 2024 nootropic |
|
|
||
Round Table Discussion →
Business →
Retailer/Product Discussion →
J 147 Powder to Treat Alzheimer’s DiseaseStarted by Peptide.ltd , 18 Apr 2024 j 147 powder, j 147 supplement and 1 more... |
|
|
||
Science & Health →
Brain Health →
Montelukast?Started by mp_double , 25 Jan 2024 nootropic, anti-inflammatory and 1 more... |
|
|
||
Science & Health →
Brain Health →
Nootropic Stacks →
What are the most effective NOOTROPICS based on science?Started by Forever21 , 30 Oct 2021 nootropic |
|
|
||
Science & Health →
Brain Health →
Dihexa?Started by brendan1 , 05 Sep 2021 nootropic |
|
|
0 members, 70 guests, 0 anonymous users